Key points from article :
Unity Biotechnology : senotherapeutics for eye diseases
- UBX1325 phase 1 - safe and an improvement in overall vision
Bioviva : Telomerase Reverse Transcriptase (hTERT) and Klotho gene transfer therapies
- phase 1 trials showed in increase in telomere length, biological age reduced and significant cognitive testing improvement.
CohBar : mitochondria treatments for obesity and NASH
- CB4211 phase 1a/1b - safe and led to a reduction in glucose
Denali : Parkinson’s Disease
- BIIB122 and DNL151 phase 1b - safe and achieved reductions in the biomarkers of target engagement
Scholar Rock : spinal muscular atrophy and frailty
- SRK-015/Apitegromab phase 2 - showed a meaningful motor function improvement
Biophytis : sarcopenia
- Sarconeos (BIO101) phase 2 - improvement in 400-metre walk test
Stealth BioTherapeutics : age-related macular degeneration (AMD)
- ReCLAIM-2 phase 2 - improvements in visual acuity (LLVA/BCVA)
Biosplice Therapeutics : osteoarthritis
- Lorecivivint phase 2b - safe and met primary endpoints of pain NRS (daily pain management).
- phase 3 trials already underway
Longeveron : stem cells
- Longeveron Mesenchymal Stem Cells (LMSCs) phase 2b - increase in six-minute walk test
Mesoblast : degenerative disc disease (DDD) and chronic back pain (plus a wide variety of other targets)
- Rexlemestrocel-L + Hyaluronic Acid phase 3 - effective as an opioid-paring therapy for chronic inflammatory back pain
Gensight Biologics : mitochondrial dysfunction
- LUMEVOQ (GS010) phase 3 - improvement in BCVA in Leber hereditary optic neuropathy (LHON) and retinitis pigmentosa (RP) patients
Mitotech : mitochondria-specific oxidative stress
- VISTA-1/VISTA-2 phase 3 - cleared central corneal staining (CCFS) and improved BCVA
